Exon skipping: a first in class strategy for Duchenne muscular dystrophy

ABSTRACT Introduction: Exon skipping is a therapeutic approach for Duchenne muscular dystrophy (DMD) that has been in development for close to two decades. This approach uses antisense oligonucleotides (AONs) to modulate pre-mRNA splicing of dystrophin transcripts to restore the disrupted DMD reading frame. The approach has moved from in vitro proof of concept studies to the clinical trial phase and marketing authorization applications with regulators. The first AON (eteplirsen) has recently received accelerated approval by the Food and Drug Administration in the US. Areas covered: In this review the authors explain the antisense-mediated exon skipping approach, outline how it needs be tailored for different DMD mutation types and describe the challenges and opportunities for each mutation type. The authors summarize the clinical development of antisense-mediated exon 51 skipping, and discuss methods to improve efficiency. Finally, the authors provide their opinion on current developments and identify topics for future prioritization. Expert opinion: Exon skipping development has been a learning experience for all those involved. Aside from an approved therapy, its development has yielded side benefits including the development of tools for clinical trials and has increased collaboration between academics, patients, industry and regulators.

[1]  Atsushi Nakano,et al.  A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. , 2016, Cell stem cell.

[2]  M. Hiller,et al.  Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy , 2015, Molecular therapy. Nucleic acids.

[3]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[4]  Akinori Nakamura,et al.  Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs , 2009, Annals of neurology.

[5]  Annemieke Aartsma-Rus,et al.  Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy , 2010, RNA biology.

[6]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[7]  J. Rousseau,et al.  Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method , 2016, Molecular therapy. Nucleic acids.

[8]  K. Bushby,et al.  The importance of genetic diagnosis for Duchenne muscular dystrophy , 2016, Journal of Medical Genetics.

[9]  H. Moulton,et al.  Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. , 2010, Biochimica et biophysica acta.

[10]  M. Moerland,et al.  Injection site reactions after subcutaneous oligonucleotide therapy , 2016, British journal of clinical pharmacology.

[11]  M. Wood,et al.  Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice , 2016, Nature Communications.

[12]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[13]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.

[14]  William H. Majoros,et al.  Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy , 2015, Nature Communications.

[15]  Michael J Gait,et al.  A chemical view of oligonucleotides for exon skipping and related drug applications. , 2014, Nucleic acid therapeutics.

[16]  K. Flanigan,et al.  The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development , 2015, Neuromuscular Disorders.

[17]  K. Clarke,et al.  Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice , 2015, Scientific Reports.

[18]  N. Goemans,et al.  Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study , 2016, PloS one.

[19]  K. Davies,et al.  Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers , 2015, Nature Medicine.

[20]  P. Iversen,et al.  By‐passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skipping , 2009, The journal of gene medicine.

[21]  Francesco Muntoni,et al.  Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  P. Camelliti,et al.  Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  E. Hoffman,et al.  P.103 DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study , 2016, Neuromuscular Disorders.

[24]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[25]  A. Aartsma-Rus,et al.  An update on RNA-targeting therapies for neuromuscular disorders. , 2015, Current opinion in neurology.

[26]  B. Aguilera,et al.  Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice. , 2014, Nucleic acid therapeutics.

[27]  G. van Ommen,et al.  Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.

[28]  M. Wood,et al.  Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy , 2014, Nucleic acids research.

[29]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[30]  S. Hammond,et al.  Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment , 2012, Molecular therapy. Nucleic acids.

[31]  G. van Ommen,et al.  The Facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure , 2007, BMC Medical Genetics.

[32]  H. Moulton,et al.  Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[34]  E. Hoffman,et al.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. , 2016, American journal of human genetics.

[35]  Tetsushi Sakuma,et al.  Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9 , 2014, Stem cell reports.

[36]  Christophe Béroud,et al.  Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.

[37]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[38]  G. Comi,et al.  Ataluren treatment of patients with nonsense mutation dystrophinopathy , 2014, Muscle & nerve.

[39]  Jinlin Song,et al.  Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy , 2016, PloS one.

[40]  J. T. Dunnen,et al.  Duplications in the DMD gene , 2006, Human mutation.

[41]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[42]  C. Lutz,et al.  Effect of genetic background on the dystrophic phenotype in mdx mice. , 2016, Human molecular genetics.

[43]  A. Woodcock,et al.  Two-, six-, and 12-minute walking tests in respiratory disease. , 1982, British medical journal.

[44]  A. Monaco,et al.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein , 1988, Cell.

[45]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[46]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[47]  K. Flanigan,et al.  Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene , 2014, Molecular therapy. Nucleic acids.

[48]  R. Finkel,et al.  DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy , 2008, Annals of neurology.

[49]  V. Mouly,et al.  Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations , 2016, Nucleic acids research.

[50]  V. Ricotti,et al.  Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study , 2014, The Lancet Neurology.

[51]  E. Mercuri,et al.  Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy , 2016, The Lancet Neurology.

[52]  C. Beekman,et al.  A Sensitive, Reproducible and Objective Immunofluorescence Analysis Method of Dystrophin in Individual Fibers in Samples from Patients with Duchenne Muscular Dystrophy , 2014, PloS one.

[53]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[54]  P. Iversen,et al.  Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer , 2008, Proceedings of the National Academy of Sciences.

[55]  Renzhi Han,et al.  CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[57]  Francesco Muntoni,et al.  The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[58]  Y. Hua,et al.  Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. , 2012, Nature chemical biology.

[59]  Elizabeth Vroom,et al.  Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy , 2013, Developmental medicine and child neurology.

[60]  Christophe Béroud,et al.  The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations , 2015, Human mutation.

[61]  G. Comi,et al.  24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy , 2013, PloS one.

[62]  A. Ferlini,et al.  Translational and regulatory challenges for exon skipping therapies. , 2014, Human gene therapy.

[63]  F. Gleason,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .

[64]  L. Kunkel,et al.  Dystrophin: the protein product of the Duchene muscular dystrophy locus. 1987. , 1992, Biotechnology.

[65]  M. Duddy,et al.  THE NEWCASTLE EXPERIENCE OF ANTI-MOG ASSOCIATED DISEASE , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[66]  H. Moulton,et al.  Fructose Promotes Uptake and Activity of Oligonucleotides With Different Chemistries in a Context-dependent Manner in mdx Mice , 2016, Molecular therapy. Nucleic acids.

[67]  B. Byrne,et al.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.

[68]  G. van Ommen,et al.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.

[69]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[70]  M. G. JirkaSilvana,et al.  Peptide Conjugation of 2′-O-methyl Phosphorothioate Antisense Oligonucleotides Enhances Cardiac Uptake and Exon Skipping in mdx Mice , 2014 .

[71]  A. Nakamura,et al.  Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice , 2015, Molecular therapy. Nucleic acids.

[72]  H. Moulton,et al.  Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function , 2008, Human molecular genetics.

[73]  Cindy Hamil,et al.  Evidence‐based path to newborn screening for duchenne muscular dystrophy , 2012, Annals of neurology.

[74]  G. Comi,et al.  Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes , 2014, PloS one.

[75]  G. van Ommen,et al.  Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy , 2008, BMC Medical Genetics.

[76]  Annemieke Aartsma-Rus.  Dystrophin Analysis in Clinical Trials. , 2014, Journal of neuromuscular diseases.

[77]  E. Bertini,et al.  Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy , 2014, Neuromuscular Disorders.